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Abstract
Objective Gastric cancer patients generally have a poor outcome, particularly those with advanced-stage disease which is 
defined by the increased invasion of cancer locally and is associated with higher metastatic potential. This study aimed to 
identify genes that were functional in the most fundamental hallmark of cancer, namely invasion. We then wanted to assess 
their value as biomarkers of gastric cancer progression and recurrence.
Design Data from a cohort of patients profiled on cDNA expression arrays was interrogated using K-means analysis. This 
genomic approach classified the data based on patterns of gene expression allowing the identification of the genes most 
correlated with the invasion of GC. We evaluated the functional role of a key protein from this analysis in invasion and as a 
biomarker of recurrence after curative resection.
Results Expression of secreted frizzled-related protein 4 (SFRP4) was identified as directly proportional to gastric cancer 
invasion. This finding was validated in multiple, independent datasets and its functional role in invasion was also confirmed 
using invasion assays. A change in serum levels of SFRP4 after curative resection, when coupled with AJCC stage, can 
accurately predict the risk of disease recurrence after curative therapy in an assay we termed PredictR.
Conclusions This simple ELISA-based assay can help predict recurrence of disease after curative gastric cancer surgery 
irrespective of adjuvant therapy. The results require further evaluation in a prospective trial but would help in the rational 
prescription of cancer therapies and surveillance to prevent under or over treatment of patients after curative resection.
Keyword SFRP4 · Gastric cancer · Invasion · Biomarker · Recurrence
Introduction
Gastric cancer (GC) is the fifth most common cancer 
worldwide and the third-highest cause of cancer-related 
deaths [1]. In countries lacking established screening 
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programs GC is often diagnosed at an advanced stage con-
tributing to the high mortality rate. In most Western coun-
tries the overall 5 year survival rate is less than 30% [2].
Although there are a variety of prognostic measures [3, 
4], the best predictor of recurrence for GC is the patho-
logical TNM stage using the AJCC/UICC staging system. 
Invasion, measured by T-stage, is a fundamental prop-
erty of cancer [5, 6] and the identification of key genes 
involved causally in invasion represent ideal candidates 
for therapeutics and diagnostic markers for GC.
We previously utilized mRNA expression analysis of 
tumour and adjacent normal samples of gastric origin to 
identify molecular signatures characteristic of premalignant 
lesions and of histological subtypes of GC [7]. The same 
data set has been interrogated in this study and has identified 
secreted frizzled-related protein 4 (SFRP4) as a gene highly 
correlated with tumour invasion or T-stage. SFRP4’s role in 
invasion was validated using independent gene expression 
data sets, immunohistochemistry and in vitro model sys-
tems. We then exploited the secreted nature of the SFRP4 
protein to develop an ELISA-based assay (SFRP4 ratio) 
which, when used in conjunction with existing clinical vari-
ables, is able to predict disease recurrence in GC patients 
after curative resection with a high degree of accuracy.
Materials and methods
Patients and samples
Tumour samples were collected from patients undergoing 
curative resection for GC in Melbourne. Blood samples 
were collected at the time of surgery and at indicated inter-
vals post-operatively.
Microarray analysis
cDNA microarrays (GSE2669) on tumour specimens were 
run previously [7]. Clinical characteristics of patient sam-
ples are described in Table S1. All continuous variables 
were considered as parametric data and analysed with 
ANOVA using the Benjamini–Hochberg false discovery 
rate for multiple correction [8]. K-means clustering analy-
sis did not include correction for multiple testing and was 
conducted in Genespring version 4.2 (Agilent Technolo-
gies Inc., California).
Microarray Validation cohorts
Validation cohorts were selected based on their genomic 
platforms and the availability of clinical information. 
Australian Gastric (n = 99; GSE51105) [9] (see Table S1) 
and Singapore Gastric (n = 178; GSE15459)[10] cohorts 
were profiled using Affymetrix U133 plus2 arrays. The 
TCGA STAD gastric cohort was profiled using RNA-seq 
[11].
Immunohistochemistry
Immunostaining was performed on tissue microarrary 
(TMA) sections using anti-SFRP4 antibodies (1:250; pro-
vided by Lisa Horvath [12]) and the DAKO LSAB + kit 
(DAKO), following the manufacturer’s protocol.
Overall survival and relapse‑free survival analysis
Australian and Singapore datasets were analysed for 
Relapse-free (RFS) and overall survival (OS) using the Bar-
code [13] algorithm. Validation using the public database 
Kaplan–Meier plotter (KMplot) [14] was performed using 
default settings. OS of the TCGA dataset was interrogated 
using the Survexpress portal [15].
Genes and pathways correlated with SFRP4
Genes correlated with SFRP4 were identified in the Aus-
tralian and TCGA cohorts using R and the cBIOPORTAL 
[16, 17] interfaces respectively. Genes with Pearson correla-
tion ≥ 0.6 were identified and duplicate genes were removed. 
Genes common to both datasets were analysed using Reac-
tome to identify functional pathways [18].
Cell culture
The human GC cell lines AGS, SNU-1 and NCI-N87 were 
obtained from the American Type Culture Collection (Rock-
ville, MD, USA). Cells were cultured in DMEM (AGS) 
or RPMI (SNU-1 and NCI-N87) supplemented with 10% 
fetal bovine serum, penicillin (100 U/ml) and streptomycin 
(100ug/ml) (all from Invitrogen, Carlsbad, CA). Cell lines 
were verified mycoplasma negative and identities were veri-
fied using the PowerPlex HS16 System kit (Promega).
shRNA knockdown
Verified shRNA clones were obtained from the Open Bio-
systems pGIPz library (Victorian Centre for Functional 
Genomics). shRNA-expressing lentiviral plasmids were 
transfected using Lenti-X packaging vectors into HEK293T 
cells (Open Biosystems). Viral containing media was col-
lected, filtered and stored at  − 80 °C. Target cells were trans-
duced and selected using puromycin. Knockdown was con-
firmed using quantitative real-time PCR and Western blot.
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Western blotting
Total protein was extracted using lysis buffer(50 mM Tris 
pH 8.0, 2% SDS). Western blot analysis was carried out 
using standard procedures with the following antibodies: 
anti-SFRP4 polyclonal antibody [R&D (AF1827) 1:10,000] 
and Anti-Tubulin (Sigma, clone B-5-1-2).
Proliferation and apoptosis assays
Proliferation assays were performed by seeding 5 × 104 cells/
well in 6-well plates and cell numbers were determined daily 
using the Countess (Invitrogen) system for a total of 3 days. 
Apoptosis was detected using the Apoptaq kit (Chemicon) 
using the manufacturer’s conditions. AGS and NCI-N87 
cells were seeded directly into chamber slides whilst a cyto-
spin was performed on SNU-1 cells to adhere them to the 
slide prior to fixing in methanol.
Invasion assay
Cells were synchronized by serum starvation to prevent 
proliferation during the assay. 400,000 cells in serum-free 
media ± recombinant SFRP4 (0–20 nM; R&D systems) 
were combined with matrigel and seeded into 8 µm pore 
transwells. Media containing serum was added to the bot-
tom chamber as a chemoattractant and incubated for 24 h at 
37 °C/5%  CO2. Migrated cells were fixed in formalin and 
stained with DAPI. Membranes were mounted on slides and 
quantitated by microscopy. Five microscopic fields were 
counted per membrane. Each experiment was performed in 
triplicate at least three times.
Wound healing (migration) assay
AGS cells were seeded in a dark-walled 96-well plate and 
cultured till confluent then serum starved for 24 h. The cell 
monolayer was wounded with a 1.5 × 4 mm scratch using a 
robotically driven pin and growth media replaced After 24 h 
cells were fixed using 2% PFA and stained with phalloidin 
(Molecular Probes) and DAPI. The extent of wound healing 
determined using published methods [19].
SFRP4 ELISA
SFRP4 ELISA was performed using a commercially avail-
able kit (USCNK Life Science Inc) following the manufac-
turer’s instructions. Samples represent unique cohorts of 
pre- and post-operative specimens and with at least 3 years 
follow up. A consort diagram (FigS1) details the criteria 
for sample selection. An independent validation dataset 
was obtained from South Korea. Clinical characteristics 
for all cohorts are detailed in Table1.
Statistical analysis
Data are expressed as mean ± SEM unless otherwise 
indicated. Analysis was performed using Graphpad 
prism software. K-means clustering was performed using 
cDNA expression arrays using Genespring software (Agi-
lent, USA). All analysis of Affymetrix U133 plus 2 data 
was carried out using R-package. We used SFRP4 ratio 
and TNM stage information as independent variables in 
a binary logistic regression analysis which resulted in a 
predicted probability of the combination of both variables 
predicting recurrence. This was evaluated by AROC and 
all analyses were performed in SPSS ver22 for Mac (IBM, 
Chicago).
Results
SFRP4 expression correlates with invasion
Invasion is a necessary requirement of cancer. To identify 
key genes contributing to invasion, cDNA expression array 
data previously generated in our laboratory using an Austral-
ian based cohort of 65 tumours was interrogated (GSE2669; 
See Table S1). T-stage was used as a measure of invasion of 
GC. Expression patterns positively correlated with T-stage 
were identified using the GeneSpring (Agilent Technolo-
gies Inc., California) K-means clustering algorithm. Eight 
patterns (K) of gene expression were chosen where every 
element on the 10.5 K array (incorporating 7383 genes) was 
used.
SFRP4 has been previously identified by our group as 
significantly overexpressed in GC compared to normal tis-
sue [7] and in this study was identified as one of the most 
significantly correlated genes with T-stage in this discovery 
cohort (Fig. 1a) and given its secreted nature was selected 
for further investigation.
A second Australian based cohort was utilised for further 
validation. This cohort consisted of 99 GC cases (including 
43 samples which were also profiled in the cDNA array dis-
covery cohort) and 40 normal/premalignant samples profiled 
using Affymetrix 133 plus2 arrays (GSE51105; Table S1).
The expression of SFRP4 during progression to GC was 
explored(Fig.  1b). Compared to normal gastric mucosa 
(n = 7) the premalignant conditions chronic gastritis (n = 22, 
p = 0.0077) and intestinal metaplasia (n = 21, p = 0.0031) both 
demonstrated elevated SFRP4 expression. SFRP4 expression 
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was highest in the all GC group which comprised all GC cases 
(n = 99; p < 0.0001 compared to normal). Further analysis of 
the GC cases showed the diffuse subtype (n = 39) had signifi-
cantly higher SFRP4 expression than the intestinal subtype 
(n = 50; p = 0.0004).
Increasing SFRP4 expression with T-stage was validated 
in three independent GC cohorts. Analysis of the tumour 
samples in the Australian cohort (described above) showed 
that SFRP4 expression levels increased incrementally with 
advanced T-stage (Fig. 1c; p = 0.003; Kruskal–Wallis test). 
Fig. 1  Identification of SFRP4 as the gene most correlated with inva-
sion. cDNA array expression data was generated for 65 tumours of 
known T-stage. a K means clustering was performed based on depth 
of invasion (T stage). Overall patterns of gene expression (y-axis) 
using depth of invasion as a continuous variable (x-axis) visualis-
ing all 7383 genes were generated. SFRP4 (black line) was identi-
fied as the gene most correlated with invasion in this dataset. Find-
ings were then validated over independent platforms and datasets. b 
SFRP4 expression in gastric tissues. 146 gastric tissues were profiled 
using Affymetrix U133 plus 2 arrays and stratified according to tis-
sue type. Histologically normal gastric tissues [NN (n = 7)] exhib-
ited significantly lower SFRP4 expression than other benign tissues 
[chronic gastritis (CG (n = 22); p = 0.0077)] and intestinal metaplasia 
[IM (n = 23; p = 0.0031)]. Highest levels of SFRP4 expression were 
observed in gastric tumour samples (n = 99; p < 0.0001). Further 
analysis of the 2 histological subtypes showed SFRP4 expression 
to be highest in diffuse GC (n = 39) compared to intestinal gastric 
cancer (n = 50; p = 0.0004). Mann–Whitney test was used for analy-
sis. SFRP4 expression based on T-stage was determined in (c) an 
updated Australian data set of 99 tumours (p = 0.003; Kruskal–Wallis 
test) and the (d) Singapore dataset (n = 178; p = 0.009 Kruskal–Wal-
lis test) were run on Affymetrix Human U133 plus 2 arrays. Each 
panel represents an individual probe for SFRP4 on the array. e The 
data was also validated using the TCGA RNASeq data set (n = 255; 
p = 2 × 10–5 Kruskal–Wallis test) (f) SFRP4 protein expression was 
determined by IHC on a TMA. Staining was quantitated using a 
semi-quantitative scale from 0 (no staining; white bar), 1 + (blue bar), 
2 + (red bar) and 3 + (black bar) (h) representative images showing 
staining of normal gastric mucosa and an intestinal type GC (IGC). 
Images × 10 and magnified × 40
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Table 1  Clinical characteristics of ELISA cases
Pilot set Test set Korean set
Parameter Recurrence Non-recurrence Recurrence Non-recurrence Recurrence Non-recurrence
Age at surgery [years (range)] 60.7 (33–83) 67.1 (55–78) 63.6 (33–83) 64.13 (43–78) 53 (33–75) 60 (43–81)
Gender
 Male 8 10 28 21 3 17
 Female 3 3 8 10 3 5
Type II diabetes
 Y 0 1 4 4 1 3
 N 11 12 32 27 5 19
Tumour location
 Cardia 4 1 8 5 0 0
 Non cardia 7 12 28 26 6 22
H. pylori status
 Positive 6 6 19 17 2 3
 Negative 4 4 9 10 2 9
 Unknown 1 3 8 4 2 10
Chemo-radiotherapy
 Neo-Adjuvant
  No Adjuvant 9 13 33 30 6 22
  Adjuvant 2 0 3 1 0 0
 Adjuvant
  No Adjuvant 4 7 12 20 UNK UNK
  Adjuvant 7 6 24 11 UNK UNK
 Palliative
  No Palliative 3 N/A 19 N/A UNK N/A
  Palliative 8 N/A 13 N/A UNK N/A
  ND 0 N/A 4 N/A UNK N/A
 Pathology
  Diffuse 4 3 14 8 2 15
  Intestinal 6 8 12 20 3 7
  Mixed 1 0 7 1 1 0
  Adenocarcinoma 0 1 2 1 0 0
  Adenosquamous 0 1 1 1 0 0
 Differentiation
  Well 0 1 0 1 0 0
  Moderate 4 4 10 10 2 5
  Poor 6 6 20 18 3 13
  Undifferentiated 1 2 6 2 1 4
 T stage
  T1 0 2 0 7 0 0
  T2 3 4 5 11 0 1
  T3 8 7 29 13 1 8
  T4 0 0 2 0 5 13
 AJCC 6th stage
  IA 0 2 0 7 0 0
  IB 1 2 1 7 0 0
  II 3 5 10 9 0 0
  IIIA 5 2 16 4 0 4
  IIIB 1 2 3 4 1 5
  IV 1 0 6 0 5 13
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Due to the limited number of T4 samples available, these 
were grouped with the T3 samples. Expression data were 
obtained from 178 independent GC samples originating from 
Singapore. T-stage information was available for 152 of these 
cases. SFRP4 mRNA expression data for these cases is repre-
sented in Fig. 1d (p = 0.009; Kruskal–Wallis test). The STAD-
TCGA dataset contains RNA-Seq data for 255 GC cases with 
known T-stage that also significantly validated the observation 
(Fig. 1e; p = 2 × 10–5; Kruskal–Wallis test. All three datasets 
consistently demonstrate increasing SFRP4 expression with 
more advanced T-stage.
Expression of SFRP4 protein mirrored the mRNA result. 
Immunohistochemistry of SFRP4 was performed and staining 
was assessed semi-quantitatively on a scale 0–3 + . Increased 
SFRP4 protein expression was observed in T3 compared with 
T1/T2 tumours (Fig. 1f). SFRP4 was overexpressed in the 
majority of gastric cancers and absent in normal gastric tissue 
(Fig. 1g).
Elevated SFRP4 mRNA expression predicts poor 
prognosis
Affymetrix array-derived data were used to determine 
whether tumour SFRP4 mRNA expression levels could 
reliably predict prognosis. The Barcode method [13] of 
analysis which uses a binary representation of expression 
data was used to classify samples as having high or low 
SFRP4 mRNA expression. Relapse-free survival (RFS) 
indicated that high SFRP4 mRNA expression levels were 
correlated with poor prognosis and patients with low 
SFRP4 expression levels had a significantly lower risk 
of recurrence in both the Australian (p = 0.01; Fig. 2a) 
and Singapore (p = 0.04; Fig. 2b) datasets. These findings 
were also validated using the gastric cohorts in the KMplot 
database (p = 0.003; Fig. 2c) [14]. Survival data were lim-
ited for the TCGA dataset with no RFS data available.
A similar analysis with overall survival as an endpoint 
indicates that high SFRP4 expression correlates with poor 
survival, irrespective of T-stage in all four cohorts studied 
(Australian p = 0.12 Fig. 2d; Singapore p = 0.002 Fig. 2e; 
KMplot gastric datasets p = 2.4 × 10–5 Fig. 2f and TCGA 
STAD datasets p = 0.0336 Fig. 2g).
SFRP4 has a functional role in invasion
In view of the association with T stage, we wanted to exam-
ine the role of SFRP4 in the mechanism of invasion. shRNA 
was used to knockdown SFRP4 expression in GC cell lines 
AGS, SNU-1 and NCI-N87. Western blot was used to con-
firm knockdown of SFRP4 expression at the protein level 
(Fig. S2A–C) and quantitation of knockdown is shown in 
Fig. S2D–F). The best overall knockdown was observed 
Table 1  (continued)
Pilot set Test set Korean set
Parameter Recurrence Non-recurrence Recurrence Non-recurrence Recurrence Non-recurrence
Surgery type
 Proximal gastrectomy 3 1 6 1 0 0
 Distal gastrectomy 4 6 11 14 0 15
 Total gastrectomy 1 5 15 15 6 7
 Oesophagogastrectomy 3 1 4 1 0 0
Margins
 R0 11 12 32 30 4 22
 R1 0 1 4 1 2 0
Recurrence type
 Local 1 0 3 0 0 0
 Distant 5 0 22 0 5 0
 Both 5 0 11 0 1 0
 None 0 13 0 31 0 22
Time till recurrence 25.6 (5.9-43.5) N/A 21.1 (2.8-77.4) N/A 93 (30.6-233.23) N/A
N/A not applicable
UNK unknown
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using construct #3 (Fig. 3a–f) which was then used for sub-
sequent experiments.
Potential confounding effects of SFRP4 knockdown on 
proliferation (Figs. S2G–) and apoptosis (Figs. S2I–L; Fig. 
S3A) were excluded.
A critical requirement for tumour invasion is the abil-
ity of the cancer cells to penetrate the extracellular matrix 
and ultimately invade into adjacent structures. We utilised 
invasion assays to quantitate the ability of GC cells to 
invade through matrigel in vitro. AGS cells with reduced 
SFRP4 expression (AGS-SFRP4#3) exhibited a significant 
(72%) reduction in invasion compared to the non-targeting 
control (Fig. 3g; AGS-scramble; p = 0.0005; t test). Pre-
incubation of knockdown cells with recombinant human-
SFRP4 restored the invasion capacity of the cells to invade 
back to basal levels in a dose-dependent manner (Fig.
S3B). The addition of 20 nM recombinant SFRP4 protein 
to wild-type cells also significantly enhanced their ability 
to invade over baseline Fig. 3g (p = 0.02; t test). This sug-
gests the secreted form of SFRP4 can help drive invasion. 
Similar results were obtained with SNU-1 (p = 0.05) and 
NCI-N87 (p = 0.04; t test) cells, which also exhibited sig-
nificant reduction (77% and 68% respectively) of invasive 
ability after SFRP4 knockdown (Figs.3h, i, respectively). 
Representative images of invasion for all cell lines tested 
are shown in Fig. S3C.
Migration assays showed that reduced SFRP4 levels 
inhibited the migration of AGS cells (p = 0.007; Fig. S3D). 
This assay was only performed for the AGS cell line as the 
other cell lines do not grow in a uniform monolayer, which 
is required for this assay.
Taken together, the validation and functional data 
described above suggest a functional role for secreted 
SFRP4 in the invasion of GC. To further explore this gene 
expression data from the Australian and TCGA cohorts was 
interrogated to identify genes most correlated with SFRP4 
(447 and 64 genes, respectively; Table S2 and Fig. S4A). 
Genes common to both datasets (n = 53; Table S2 and Fig. 
S4A) were further analysed using the Reactome Database 
[18]. Five of the top 8 enriched pathways are related to 
Fig. 2  Effects of SFRP4 expression on relapse free (RFS) and over-
all survival (OS). Samples with available survival data were classi-
fied as SFRP4 high (red) or low (black) based on mRNA expression 
using the Barcode method [Australian (n = 99) and Singapore cohorts 
(n = 141)] or default settings of the kmplot interface (combined 
independent datasets (n = 876) or Survexpress for the TCGA STAD 
cohort (n = 352). a-c Kaplan–Meier curves were generated showing 
RFS. The results indicate that high SFRP4 expression levels were 
correlated with poor prognosis whilst patients harbouring tumours 
with low SFRP4 expression levels had a significantly lower risk of 
recurrence [p = 0.01 (Australian data set); p = 0.04 (Singapore data 
set); p = 0.003 (combined independent data set) log-rank test]. A 
similar analysis was performed using OS as an endpoint (d) Australia 
dataset p = 0.12 (e) Singapore dataset p = 0.002 (f) combined inde-
pendent data set p = 2.4 × 10–5 (g) TCGA STAD dataset (p = 0.0336)
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extracellular matrix organisation, composition and degra-
dation. (Fig. S4B).
Given that disruption of the extracellular matrix promotes 
epithelial to mesenchymal transition (EMT) and ultimately 
invasion the Australian cohort was used to correlate SFRP4 
expression to that of key genes involved in EMT. SFRP4 was 
found to be significantly positively correlated to SNAI1, SLUG, 
VIM, ZEB1, ZEB2 and TWIST1 and negatively correlated to 
CDH1 (Fig. S5). These findings suggest that EMT may be a 
large component of the mechanism of action of SFRP4.
Utility of SFRP4 as a biomarker of recurrence
Based on the finding that the secreted form of SFRP4 has 
biological relevance for GC we investigated the possibility 
that serum or plasma SFRP4 levels could be used as a diag-
nostic test for patients with GC or as a prognostic biomarker. 
SFRP4 ELISA showed a high patient-to-patient variation of 
both non-cancer volunteers and GC patients with no overall 
difference between the two groups (data not shown) suggest-
ing that baseline or preoperative blood SFRP4 levels are not 
a suitable for diagnosis of GC.
The role of SFRP4 in invasion and potentially metastasis 
suggested a change in plasma levels within an individual 
may be useful in predicting patient recurrence after cura-
tive resection. We sought to determine whether SFRP4 lev-
els changed after curative resection when compared to an 
individuals baseline level to test the change in SFRP4 level 
as a biomarker of tumour recurrence. We utilised a unique 
cohort of patients who had undergone curative resection and 
Fig. 3  shRNA knockdown of gastric cancer cell lines. shRNA 
based lentiviral constructs were used to knockdown SFRP4 expres-
sion in (a) AGS, b SNU-1 and (c) NCI-N87 gastric cell lines using 
the SFRP4#3 construct and validated by Western blot. d-f Quan-
titation of knockdown was determined using Image J (g-i) Invasion 
assays were performed using WT cells, WT cells + scramble and WT 
cells + SFRP4 lentivirus. Reduction of SFRP4 expression resulted in 
a significant reduction in invasive capabilities (compared to scram-
ble controls) in all cell lines. Pre-incubation of the cells with 20 nM 
recombinant human SFRP4 was able to restore the invasive ability of 
the knockdown cells to wild-type levels and, in the case of AGS and 
NCI-N87 cell lines was able to enhance the invasive capability of WT 
cells. Data show means ± SD. of at least three independent experi-
ments. *p < 0.05, **p < 0.01
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were followed for up to 10 years (mean 7.3 years in non-
recurrence cases) with serial blood samples.
The pilot phase analysed 11 patients with recurrent 
disease from our Australian cohort and measured SFRP4 
levels in plasma: pre-operatively (baseline-levels); post-
operatively (first blood drawn post-surgery); pre-recurrence 
(blood drawn before clinical diagnosis of recurrence) and; 
post-recurrence (first blood drawn after clinical diagnosis 
of recurrence). The control group comprised 13 patients, 
matched for stage, treatment, age and gender and who had 
undergone curative gastric resection with no documented 
recurrence. For the control group, plasma collected: pre-
operatively (baseline-levels); post-operatively (first blood 
drawn post-surgery) and; a time point at least 36 months 
post operatively was analysed. This time point was selected 
as most GC patients who recur do so within 36 months of 
surgery. Patient selection criteria (Fig. S1) and clinical char-
acteristics (Table 1) were matched in both groups.
Plasma SFRP4-levels were determined for all samples 
using ELISA and were measured as a ratio against the indi-
vidual patient’s baseline level, to control for individual 
variation. (Fig. 4a). SFRP4 ratio was defined as the ratio of 
the first post-operative blood SFRP4 level and the baseline 
SFRP4 level for individual patients. The data indicate that 
SFRP4 ratios remained constant for patients who did not 
develop a recurrence of disease, whilst there was an early 
and sustained increase over baseline of SFRP4 plasma ratios 
in patients who ultimately recurred (Fig. 4a). There was a 
clear increase in circulating SFRP4 levels in patients who 
develop cancer recurrence that occurs very early after cura-
tive resection and was maintained, in some cases for years, 
before the clinical diagnosis of recurrence (Fig. S6). We 
propose this novel finding could be exploited as a clinical 
biomarker of recurrence that would facilitate triage to more 
aggressive therapy or surveillance in the high-risk group.
Comparison of SFRP4 ratio and existing 
blood‑based biomarkers
There are no established prognostic or surveillance bio-
markers recommended for GC. We compared SFRP4 
ratio with existing clinical biomarkers for gastrointesti-
nal cancer and upper gastrointestinal cancer, CEA and 
CA19-9 respectively, to evaluate their ability to pre-empt 
Fig. 4  Secreted SFRP4 as a biomarker for gastric cancer. a Plasma 
samples collected over a period of 36 months from a pilot cohort of 
clinically matched Australian GC patients, 11 of whom ultimately 
recurred (red line) and 13 who did not recur (black line) were sam-
pled using a commercial ELISA based assay. For each patient, all 
results were normalised to that of their pre-operative blood sample 
(SFRP4 ratio). b The ability of SFRP4 ratio to predict recurrence 
was tested in a series of patient samples collected from patients who 
have previously developed recurrent disease. For each patient CEA, 
CA19-9 and SFRP4 ratio levels were determined and compared using 
plasma collected pre-operatively, the first post-operative blood, pre 
documented recurrence (pre-recurrence) and following clinically 
confirmed recurrence (post-recurrence). Dotted lines represent the 
clinically utilised cut-offs for each test (CEA; 5 ng/mL and CA19-9; 
35U/mL). For SFRP4 ratio the pre-determined cut off ratio of 1.2 was 
used. CEA yielded various results and was only able to predict recur-
rence in a small percentage of cases. CA19-9 only showed positive 
results after recurrence was detected clinically. These data negate the 
use of both these tests as a biomarker of GC. SFRP4 ratios hows the 
promising ability to predict recurrence soon after curative resection
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and detect recurrence. Pre-operative, post-operative, pre-
recurrence and post-recurrence bloods from GC patients 
were analysed using the standard CEA and CA19-9 test-
ing methods performed by the Peter MacCallum Cancer 
Centre Pathology service. Figure 4a shows representative 
data for 3 patients. CEA and CA19-9 show limited ability 
to detect existing recurrent disease prior to the clinical 
diagnosis of the recurrence, which provides no clinical 
advantage. SFRP4 ratio is the only marker elevated before 
recurrence, often months or years before the recurrence is 
clinically diagnosed.
SFRP4 ratio and AJCC combination is the most 
accurate predictor of recurrence (PredictR)
Given the superior ability of SFRP4 ratio to predict recur-
rence in comparison to existing biomarkers we then sought 
to determine whether this was independent of currently 
accepted clinical prognosticators, namely pathological TNM 
stage. Logistic regression was used to assess the role of each 
of 5 different models: (i) T-stage alone; (ii ) N-stage alone; 
(iii) SFRP4 ratio alone; (iv) pathological AJCC stage (7th 
edition) alone and; (v) SFRP4 ratio and pathological AJCC 
(7th edition) in combination using a validation cohort of 
Fig. 5  Development of an a test to predict recurrence of gastric can-
cer post resection (PredictR) (a) ROC and Logistic regression were 
used to determine whether SFRP4 ratio was predictive of recurrence 
independent of T-stage, N-stage and AJCC stage using an extended 
validation cohort of 67 Australian GC patients (36 recurrence and 
31 non-recurrence). SFRP4 ratio and AJCC stage alone were simi-
lar in predictive accuracy when used independently, however when 
combined (PredictR) their accuracy was significantly improved. Odds 
ratio of recurrence using SFRP4 ratio alone at a cutoff of 1.21 was 
7.2 (95% CI 2.5–20.6; p < 0.001) b Area under ROC of the different 
groups showing highest accuracy in the PredictR (SFRP4ratio/AJCC) 
combination using a logistic regression model with 95% CI (p-value 
for the difference with AJCC alone = 0.044) c This was further vali-
dated in a second independent cohort of 28 Stage III Korean patients 
(Korean validation cohort) 6 recurrence and 22 non-recurrence) and 
found an accuracy (AUC) of 83% using SFRP4 ratio. Odds ratio of 
recurrence with SFRP4 ratio at a cutoff of 1.21 was 16 (95% CI 1.5–
171.2;p value = 0.002)
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67 clinically matched GC patients from Australia which 
included the pilot group (Clinical data in Table 1).
Models of prediction were evaluated using an ROC analy-
sis (Figs.5a, b). The SFRP4 ratio/AJCC combination was 
termed PredictR and had an AUC of 85% (95%CI76–94%) 
for prediction of recurrent disease whereas pathological 
AJCC (the current preferred predictor of recurrence) was 
77% (95%:CI 66–89%) and the p-value of this difference was 
0.044. It is notable that SFRP4 ratio alone had an independ-
ent AUC of 76% (95% CI65–88%) and odds ratio 7.12 (95% 
CI2.5–20.6; p < 0.001) that the combination with pathologi-
cal TNM (AJCC) was additive in the prediction accuracy.
This result was further validated using a prospectively 
collected series from South Korea. Based on the excellent 
prognosis of these patients, we selected cases with simi-
lar clinical profiles to our Australian cohort and we used 
27 South Korean AJCC stage III cases. The ROC curve 
(Fig. 5c) reveals PredictR has an independent AUC of 83% 
(95% CI:63–98%) for prediction of recurrence in these 
patients. We performed logistic regression to determine if 
SFRP4 ratio alone at a threshold value of 1.2 was predictive 
of recurrence in this cohort and found an Odds Ratio of 16 
(95% CI1.5–171.2; p = 0.022) independent of stage corre-
sponding to a positive predictive probability of recurrence 
using SFRP4 ratio alone of 84%.
Discussion
We have previously identified SFRP4 as consistently over-
expressed in all GC subtypes when compared to correspond-
ing normal tissue [7]. Other studies have reported similar 
findings in a variety of solid cancers [12, 20–22]. Epige-
netic downregulation of secreted frizzled-related proteins 
and SFRP4 by promoter methylation has been described in 
some cancer types [23, 24] however in GC this seems to 
be restricted to the SFRP2 gene [25]. Here we show that 
elevated tumour SFRP4 expression is associated with poor 
prognosis in GC which was also recently reported by others 
[26]. These authors used an in silico based approach to show 
that overexpression of SFRP4 is correlated with poor sur-
vival in glioma, colorectal, clear cell kidney, liver, head/neck 
SCC and bladder cancers but not breast, lung, pancreatic, 
ovarian or oesophageal cancer, suggesting disparate roles 
for this protein in different tumour contexts [26].
Here, we used multiple clinical genomic cohorts of GC 
to validate the finding that SFRP4 is over-expressed in more 
invasive cancers. Invasion is an important hallmark of malig-
nancy [5, 6]. Our analysis was found to significantly predict 
the risk of recurrence of patients after curative resection of 
their GC. SFRP4 tumour expression was previously reported 
as part of a 6-gene signature which was able to predict recur-
rence of GC [27]. Further, the prognostic value of SFRP4 
overexpression in resectable GC was recently validated in 
archived samples from the CLASSIC trial cohort [28]. We 
showed elevated SFRP4 was significantly associated with 
poor overall survival in the Singapore, KMplot and TCGA 
cohorts. A similar trend was also seen in the Australian 
cohort but this was not significant most likely due to the 
small sample size.
Despite being well known for their role as WNT modu-
lators and tumour suppressors there is emerging evidence 
that suggests the SFRPs may have alternate functions related 
to the promotion of carcinogensis in a context and tumour 
type-dependent manner [29]. Indeed a pan-cancer, in silico 
study [26] suggests that despite their proposed roles as Wnt 
antagonists SFRP2 and SFRP4 may promote processes such 
as cellular invasion and metastasis. This is consistent with 
our findings which show that SFRP4 expression is correlated 
with T-stage. We observed that genes correlated with SFRP4 
are functionally enriched for signalling and extracellular 
matrix pathways both of which are disrupted during EMT, 
a cellular de-differentiation process by which epithelial cells 
lose cell adhesion capabilities and gain invasive properties 
[30].
We find that reducing SFRP4 levels using shRNA resulted 
in the reduced invasion of different subtypes of gastric can-
cers in vitro. This novel finding introduces a unique variation 
to the treatment of cancer since we have found inhibiting 
SFRP4, while not oncocidal, may be considered oncostatic 
(limiting invasion and potentially metastasis).
A second novel finding describes an assay which uses 
SFRP4 plasma levels in two blood samples of humans with 
GC. The first is taken immediately before surgery for cura-
tive resection and the second at approximately 1 month 
following surgery. The ratio of these values (SFRP4 ratio) 
allows for prediction of recurrence many months or years 
into the future with an early and sustained increase in SFRP4 
levels observed following curative surgery in patients whose 
cancer ultimately recurred. The only other use of SFRP4 as 
a biomarker was in the context of Type2 diabetes mellitus 
[31]. We considered the potential confounding of Type2 dia-
betes mellitus in our study participants and found an equiva-
lent distribution of patients in our cohort (Table1).
There are currently no effective non-invasive prognostic 
biomarkers for the early detection of GC or its recurrence 
following curative resection. Pepsinogen I/II ratio [32] has 
been used as a screening test in some countries but is not 
useful as a surveillance tool. Currently, there are no reli-
able circulating biomarkers for monitoring treatment of GC. 
Clinicians variably use CEA (carcinoembryonic antigen), 
CA19-9 and CA72-4 as serum markers. These assays were 
used mainly as diagnostic biomarkers rather than markers of 
prognosis. CA72-4 was reported with significant specificity 
(97%) for GC [33], but because of poor sensitivity (47%) 
is not used in population-based screening or for disease 
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follow-up. Our SFRP4 ratio biomarker outperforms current 
serum-based tests in pre-empting recurrence many months 
prior to clinical detection of recurrence. Whilst signifi-
cant when used alone, the predictive value of SFRP4 ratio 
is further improved with the addition AJCC staging data 
obtained at the time of surgical resection. We believe this 
is a major step forward in providing more precise informa-
tion to patients and potentially changing their management 
decisions. This observation however needs to be replicated 
in prospective trials. A number of potential biomarkers for 
GC, based on genetic and epigenetic changes, have been 
described. However, none of these have translated into clini-
cal use, again due to lack of sensitivity and/or specificity 
(reviewed in [34, 35]).
One limitation of this study reflects the current clinical 
care of GC patients after curative resection. Namely, the 
guidelines for postoperative management of GC recommend 
clinical follow-up but no active radiological follow-up [36] 
because there is currently limited evidence suggesting that 
early detection of recurrence impacts patient survival. As a 
result of current clinical practice, patients within this cohort 
were only investigated for recurrence after clinical suspicion. 
It is conceivable that recurrence in our PredictR positive 
patients may have been detected earlier if regular surveil-
lance was the standard of care. We believe the results pre-
sented in this study warrant further clinical trial to validate 
the efficacy of in a prospective cohort and we believe may 
lead to practice change in GC management by allowing us 
to identify patients at risk of recurrence very early and allow 
targeted therapy or more intensive surveillance of that high-
risk group.
In conclusion, we have shown that SFRP4 is over-
expressed in the majority of gastric cancers and its high 
expression leads to a poor outcome. We report for the first 
time that SFRP4 functions in the cellular invasion of GC 
and this is the reason for the poor prognosis and that inhibi-
tion of SFRP4 leads to abrogation of invasion in vitro. This 
study also found that SFRP4 levels in patients after curative 
resection of gastric cancer predicts GC recurrence at an early 
stage. We hypothesise that resection of the primary tumour 
triggers the establishment of a permissive environment for 
pre-seeded micrometastases to begin to invade, prior to the 
clinical detection, and that this evidenced by an early and 
sustained increase in serum SFRP4 levels in patients who 
ultimately recur. Our PredictR assay may allow triage of 
patients to a high-risk group warranting more aggressive 
therapy and increased surveillance. This is a step towards 
precision medicine given PredictR may be used in conjunc-
tion with a companion therapeutic that could target SFRP4 
inhibition. These will need to be tested in future clinical 
trials to determine whether this strategy leads to improved 
clinical outcomes.
Acknowledgements We thank the VCFG for providing the shRNA 
constructs and Lisa Horvath (Garvan Institute of Medical Research) 
for providing the SFRP4 antibody used for IHC. We also acknowl-
edge David Faulkner (Peter MacCallum Cancer Centre Department of 
Pathology) for assistance with the CEA and CA19-9 testing.
Funding This research was supported by funding from the Peter Mac 
Foundation (RB), VCA (Early Career Seed Grant to RB), No Stomach 
For Cancer Foundation (AB/RB), NHMRC grants ID454584 (AB), 
ID1030980 (AB), The Li Ka Shing Foundation (AB) and philanthropic 
funding from the Estate of George Wilson and an anonymous donor.
Compliance with ethical standards 
Conflict of interest The authors have declared no potential conflicts 
of interest.
Ethics approval and consent to participate All participants provided 
written informed consent. All procedures were accepted by the Institu-
tional Review Board of the Peter MacCallum Cancer Centre and each 
of the collection centres.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo 
M, et al. Cancer incidence and mortality worldwide: sources, 
methods and major patterns in GLOBOCAN 2012. Int J Cancer. 
2015;136(5):E359–86.
 2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang 
XS, et al. Global surveillance of cancer survival 1995–2009: 
analysis of individual data for 25,676,887 patients from 279 pop-
ulation-based registries in 67 countries (CONCORD-2). Lancet. 
2015;385(9972):977–1010.
 3. Monig S, Baldus SE, Collet PH, Zirbes TK, Bollschweiler E, 
Thiele J, et al. Histological grading in gastric cancer by Goseki 
classification: correlation with histopathological subtypes and 
prognosis. Anticancer Res. 2001;21(1B):617–20.
 4. Luebke T, Baldus SE, Grass G, Bollschweiler E, Thiele J, Dienes 
HP, et al. Histological grading in gastric cancer by Ming clas-
sification: correlation with histopathological subtypes, metas-
tasis, and prognosis. World J Surg. 2005;29(11):1422–7 (Epub 
2005/10/14 (discussion 8)).
 5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 
2000;100(1):57–70.
 6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next genera-
tion. Cell. 2011;144(5):646–74.
601SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence 
1 3
 7. Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, et al. 
Distinctive patterns of gene expression in premalignant gastric 
mucosa and gastric cancer. Cancer Res. 2003;63(10):2569–77.
 8. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling 
the false discovery rate in behavior genetics research. Behav Brain 
Res. 2001;125(1–2):279–84.
 9. Busuttil RA, George J, Tothill RW, Ioculano K, Kowalczyk A, 
Mitchell C, et al. A signature predicting poor prognosis in gas-
tric and ovarian cancer represents a coordinated macrophage and 
stromal response. Clin Cancer Res. 2014;20(10):2761–72 (Epub 
2014/03/25).
 10. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic 
pathway combinations predict clinical prognosis in gastric cancer. 
PLoS Genet. 2005;5(10):e1000676 (Epub 2009/10/03).
 11. Cancer Genome Atlas Research N. Comprehensive molecu-
lar characterization of gastric adenocarcinoma. Nature. 
2014;513(7517):202–9.
 12. Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saun-
ders DN, et al. Secreted frizzled-related protein 4 inhibits pro-
liferation and metastatic potential in prostate cancer. Prostate. 
2007;67(10):1081–90 (Epub 2007/05/04).
 13. McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. The 
Gene Expression Barcode: leveraging public data repositories to 
begin cataloging the human and murine transcriptomes. Nucleic 
Acids Res. 2011;39(Database issue):D1011–5.
 14. Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, 
et al. Cross-validation of survival associated biomarkers in gastric 
cancer using transcriptomic data of 1065 patients. Oncotarget. 
2016;7(31):49322–33 (Epub 2016/07/08).
 15. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, 
Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos 
A, et al. SurvExpress: an online biomarker validation tool and 
database for cancer gene expression data using survival analysis. 
PLoS ONE. 2013;8(9):e74250 (Epub 2013/09/26).
 16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, 
et al. Integrative analysis of complex cancer genomics and clinical 
profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
 17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, 
et al. The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer Dis-
cov. 2012;2(5):401–4.
 18. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, 
et al. The reactome pathway knowledgebase. Nucleic Acids Res. 
2020;48(D1):D498–503 (Epub 2019/11/07).
 19. Melani M, Simpson KJ, Brugge JS, Montell D. Regulation of 
cell adhesion and collective cell migration by hindsight and its 
human homolog RREB1. Curr Biol. 2008;18(7):532–7 (Epub 
2008/04/09).
 20. Jiang H, Li Q, He C, Li F, Sheng H, Shen X, et al. Activation of 
the Wnt pathway through Wnt2 promotes metastasis in pancreatic 
cancer. Am J Cancer Res. 2014;4(5):537–44.
 21. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt 
H, et al. Proteins from the Wnt pathway are involved in the patho-
genesis and progression of mammary phyllodes tumours. J Clin 
Pathol. 2009;62(11):1016–20.
 22. Huang D, Yu B, Deng Y, Sheng W, Peng Z, Qin W, et al. SFRP4 
was overexpressed in colorectal carcinoma. J Cancer Res Clin 
Oncol. 2010;136(3):395–401 (Epub 2009/09/05).
 23. Wu Y, Bai J, Li Z, Wang F, Cao L, Liu C, et al. Low expres-
sion of secreted frizzled-related protein 4 in aggressive pituitary 
adenoma. Pituitary. 2015;18(3):335–42.
 24. Brebi P, Hoffstetter R, Andana A, Ili CG, Saavedra K, Viscarra 
T, et al. Evaluation of ZAR1 and SFRP4 methylation status as 
potentials biomarkers for diagnosis in cervical cancer: exploratory 
study phase I. Biomarkers: Biochem Indic Of Expo, Response, 
Susceptibility To Chem. 2014;19(3):181–8.
 25. Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, et al. Fre-
quent epigenetic inactivation of secreted frizzled-related protein 
2 (SFRP2) by promoter methylation in human gastric cancer. Br 
J Cancer. 2007;97(7):895–901.
 26. Vincent KM, Postovit LM. A pan-cancer analysis of secreted 
Frizzled-related proteins: re-examining their proposed tumour 
suppressive function. Sci Rep. 2017;7:42719 (Epub 2017/02/22).
 27. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, et al. 
Development and validation of a six-gene recurrence risk score 
assay for gastric cancer. Clin Cancer Res. 2016;22(24):6228–35 
(Epub 2016/09/23).
 28. Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, 
et al. Predictive test for chemotherapy response in resectable gas-
tric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 
2018;19(5):629–38 (Epub 2018/03/24).
 29. Nfonsam LE, Jandova J, Jecius HC, Omesiete PN, Nfonsam 
VN. SFRP4 expression correlates with epithelial mesenchymal 
transition-linked genes and poor overall survival in colon cancer 
patients. World J Gastrointest Oncol. 2019;11(8):589–98 (Epub 
2019/08/23).
 30. Lamouille S, Xu J, Derynck R. Molecular mechanisms of 
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 
2014;15(3):178–96.
 31. Mahdi T, Hanzelmann S, Salehi A, Muhammed SJ, Reinbothe 
TM, Tang Y, et al. Secreted frizzled-related protein 4 reduces 
insulin secretion and is overexpressed in type 2 diabetes. Cell 
Metab. 2012;16(5):625–33.
 32. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoy-
ama M, et al. Validation of the pepsinogen test method for gas-
tric cancer screening using a follow-up study. Gastric Cancer. 
2009;12(3):158–63 (Epub 2009/11/06).
 33. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, 
Roviello F. Clinical utility of CEA, CA 19–9, and CA 72–4 in the 
follow-up of patients with resectable gastric cancer. Am J Surg. 
2001;181(1):16–9.
 34. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progres-
sion in early diagnosis and prognosis (Review). Oncology letters. 
2015;9(4):1502–8.
 35. Kanda M, Kodera Y. Recent advances in the molecular diagnostics 
of gastric cancer. World J Gastroenterol. 2015;21(34):9838–52.
 36. D’Ugo D, Biondi A, Tufo A, Persiani R. Follow-up: the evidence. 
Dig Surg. 2013;30(2):159–68.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
